NorthWest Biotherapeutics Inc (NWBO)

[GermanCol]

I first misunderstood your question.

I'm also trying to understand why. The only thing I can say about that for now is:

- I found the following statemet in the JTM article:

The MGMT gene promoter was methylated in 39.6% of patients (n=131) and unmethylated in 48.9% (n=162), with information not available for 11.5% (n=38; the missing data relates to the early patients enrolled a decade ago)

I think this confirms what you, myself and other people though about the patients with unidentified MGMT gene promoter methylation status being part of the first group of patients.

So, if we take that as a fact, my guess would be that they had technical or logistical issues with crossover at the beginning of the trial when recurrence happened. It would be great if somebody could add something about that in agreement or disagreement.